Future Directions for Immunotherapy in Ovarian Cancer
نویسندگان
چکیده
Immunotherapies involving cellular and checkpoint inhibitor approaches are under investigation in ovarian cancer and preliminary results suggest evidence of clinical benefit. Assumptions in the past of low immunogenicity of ovarian cancer appear to be changing as our new awareness of immune function activity with ovarian cancer, tumor microenvironment and molecular signaling is becoming evident. Anticancer response, survival advantage, and developing program progression have been observed in immunotherapy approaches involving ovarian cancer patients. Herein, we review current progress of cellular immunotherapy and checkpoint inhibitor approaches in ovarian cancer.
منابع مشابه
Current status of immunotherapy for the treatment of lung cancer.
Immunotherapy is a novel approach for the treatment of systemic malignancies. Passive and adaptive immunotherapy have been applied to the treatment of a wide variety of solid tumors such as malignant melanoma (1), renal cell carcinoma (2) and ovarian cancer (3). Several early clinical trials of immune based therapy for both non-small (NSCLC) and small cell lung cancer (SCLC) have demonstrated l...
متن کاملWorkshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Understanding how murine models can elucidate the mechanisms underlying antitumor immune responses and advance immune-based drug development is essential to advancing the field of cancer immunotherapy. The Society for Immunotherapy of Cancer (SITC) convened a workshop titled, "Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy" as p...
متن کاملFoxP3+ Regulatory T Cells in Peripheral Blood of Patients with Epithelial Ovarian Cancer
Background: Ovarian cancer is the fifth leading cause of death from malignancy in women. CD4 +CD25+FoxP3+ regulatory T (Treg) cells are a subset of T lymphocytes with great inhibitory impact on immune response. Objectives: To investigate the percentage of CD4 +CD25+FoxP3+ regulatory T cells in the peripheral blood of the Iranian patients with epithelial ovarian cancer compared to healthy women ...
متن کاملFuture of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملAntibody-based immunotherapy for ovarian cancer: where are we at?
Cytoreductive surgery and chemotherapy continue to be the mainstay of ovarian cancer treatment. However, as mortality from advanced ovarian cancer remains very high, novel therapies are required to be integrated into existing treatment regimens. Immunotherapy represents an alternative and rational therapeutic approach for ovarian cancer based on a body of evidence supporting a protective role o...
متن کامل